Along with successful validation on patients carrying BRCA1 and BRCA2 mutations [111], positive effects of PARPi were also observed in patients without BRCA mutations with high-grade serous or poorly differentiated ovarian carcinoma or TNBC [112]. The gene discussed is BRCA2; the disease is ovarian carcinoma.